CLINICAL TRIALS PROFILE FOR AKLIEF
✉ Email this page to a colleague
All Clinical Trials for AKLIEF
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04451330 ↗ | A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV) | Completed | Galderma R&D | Phase 4 | 2020-07-28 | The purpose of this study is to demonstrate that daily use of topical trifarotene (CD5789) 50 microgram per gram (mcg/g) cream when used in association with oral antibiotic is safe and effective for the treatment of severe AV. |
| NCT05089708 ↗ | AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation | Not yet recruiting | Galderma R&D | Phase 4 | 2021-12-31 | The purpose of this study is to evaluate the efficacy and safety of Trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle cream in the treatment of moderate acne vulagris with risk of acne-induced post inflammatory hyperpigmentation (PIH) after 24 weeks of treatment in facial acne participants |
| NCT05550337 ↗ | Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris | Not yet recruiting | Teva Pharmaceuticals, Inc. | Phase 3 | 2022-09-19 | To compare the safety and efficacy of the test (Trifarotene 0.005% cream), placebo (vehicle cream) and reference AKLIEF® (Trifarotene 0.005% cream) treatments to demonstrate clinical equivalence in subjects with acne vulgaris. |
| NCT05550337 ↗ | Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris | Not yet recruiting | Teva Pharmaceuticals USA | Phase 3 | 2022-09-19 | To compare the safety and efficacy of the test (Trifarotene 0.005% cream), placebo (vehicle cream) and reference AKLIEF® (Trifarotene 0.005% cream) treatments to demonstrate clinical equivalence in subjects with acne vulgaris. |
| NCT06063473 ↗ | A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris | Completed | Taro Pharmaceuticals USA | Phase 1 | 2023-02-22 | To demonstrate therapeutic equivalence and safety of Trifarotene cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and AKLIEF® cream in the treatment of acne vulgaris |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for AKLIEF
Condition Name
Clinical Trial Locations for AKLIEF
Trials by Country
Clinical Trial Progress for AKLIEF
Clinical Trial Phase
Clinical Trial Sponsors for AKLIEF
Sponsor Name
